Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 15, 2025, and can do so by contacting Rosen Law Firm [4][7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [5]. - The firm has been recognized for its achievements, including the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements achieved [5]. Group 3: Case Allegations - The lawsuit alleges that during the class period, MoonLake made false or misleading statements regarding its product SLK, particularly in comparison to traditional monoclonal antibodies, which led to investor losses when the truth was revealed [6].

Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from February 21, 2025 to August 28, 2025 [1][5]. Group 1: Legal Action Details - Investors who purchased Telix securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3]. - The lawsuit alleges that Telix made materially false and misleading statements regarding its prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of the Plaintiffs' Bar in 2020 [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased common stock of MoonLake between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The deadline to move the court to serve as lead plaintiff is December 15, 2025, with the lead plaintiff acting on behalf of other class members [4]. Group 2: Legal Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [5]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [5]. Group 3: Case Allegations - The complaint alleges that during the class period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of aTyr Pharma, Inc. during the specified class period of the upcoming lead plaintiff deadline on December 8, 2025, for a class action lawsuit related to misleading statements about the drug Efzofitimod [1][5]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the court by December 8, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise and reputation in handling such cases [4]. Group 3: Case Allegations - The complaint alleges that aTyr Pharma provided misleading statements regarding the efficacy of Efzofitimod, particularly concerning its ability to allow patients to taper off steroid usage completely [5]. - The lawsuit claims that when the true information became public, investors suffered damages due to the misleading nature of the statements made by the company [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Firefly Aerospace Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a report indicating that Firefly Aerospace may have misled investors regarding its business performance [1]. - Investors who purchased Firefly Aerospace securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. Group 2: Financial Performance - Firefly Aerospace reported a wider loss and lower revenue in its latest quarter, which was its first earnings report since going public [3]. - Following the earnings report, Firefly's stock price fell by 15.3% on September 23, 2025 [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Freeport-McMoRan Inc. securities between February 15, 2022, and September 24, 2025, about the upcoming lead plaintiff deadline for a class action lawsuit set for January 12, 2026 [1][3] Group 1: Class Action Details - Investors who bought Freeport-McMoRan securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit alleges that Freeport-McMoRan made false or misleading statements regarding safety at the Grasberg Block Cave mine in Indonesia, which posed significant risks to workers and the company's reputation [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4] - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company and ranking highly in the industry since 2013 [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a class action lawsuit related to the company's stock performance during the specified class period [1][3]. Group 1: Class Action Details - The class period for the Inspire Medical Systems, Inc. stock is from August 6, 2024, to August 4, 2025, inclusive [1]. - Investors who purchased common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by January 5, 2026 [3]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Inspire Medical Systems misrepresented key facts about its Inspire V sleep apnea device, including market demand and readiness for launch, leading to misleading statements that inflated investor confidence [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of America's Car-Mart, Inc. due to allegations of materially misleading business information being issued to the investing public [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased America's Car-Mart securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Performance and Market Reaction - On September 4, 2025, America's Car-Mart reported a first-quarter loss of $0.69 per share, compared to a net loss of $0.15 per share in the same period the previous year [3]. - Following the release of these results, America's Car-Mart's stock experienced a decline of 18.2% on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Primo Brands Corporation and Primo Water Corporation to secure legal counsel before the January 12, 2026 deadline for a class action lawsuit related to securities misrepresentation during specified class periods [1][5]. Group 1: Class Action Details - Investors who purchased common stock of Primo Water Corporation between June 17, 2024, and November 8, 2024, or Primo Brands Corporation between November 11, 2024, and November 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 12, 2026 [3][5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit claims that Primo Brands, formed after the merger between Primo Water and BlueTriton Brands, misrepresented key facts about the merger integration, leading investors to believe in accelerated growth and strong financial results [5]. - The defendants allegedly issued materially false and misleading statements regarding the merger's progress, which resulted in investor damages when the true details were revealed [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Perrigo Company plc securities between February 27, 2023, and November 4, 2025, due to alleged misleading statements and undisclosed issues related to the company's infant formula business [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Perrigo made materially false and misleading statements regarding its infant formula business, which suffered from significant underinvestment and required substantial capital expenditures [5]. - Allegations include significant manufacturing deficiencies in the infant formula facility, leading to overstated financial results, including earnings and cash flow [5]. - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading nature of Perrigo's positive statements about its business and operations [5]. Group 2: Class Action Participation - Investors who purchased Perrigo securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the court by January 16, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].